Plain-English translation of NCT07239310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a medical device called Neuclare that may help improve executive function—your ability to plan and solve problems—in people with mild cognitive impairment or very early Alzheimer's disease. You would continue taking your current memory medications and receive the device treatment three times a week for four weeks. Researchers want to see if this device, combined with your regular medications, can safely provide temporary improvements in thinking and planning abilities.
People with early memory loss often struggle with planning and problem-solving, and current medications have limited ability to improve these specific skills. This trial is exploring whether this new brain device could offer an additional tool to help patients maintain and temporarily improve these important thinking abilities.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would continue taking your current memory medications while being randomly assigned to receive either the Neuclare device or a sham (fake) device. Three times per week for four weeks, the device would be applied to your brain. Throughout the study, you would complete cognitive tests, have brain imaging scans, provide blood samples, and answer questions about your daily activities and quality of life. Neither you nor the study staff would know which device you received until the trial ends.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
South Korea